Trial Profile
A safety study of Doxil [doxorubicin liposomal] and Herceptin [trastuzumab] in patients with advanced HER-2 overexpressing breast cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2005 New trial record.